International AMD Genomics Consortium

International AMD Genomics Consortium
Name	International AMD Genomics Consortium
Abbreviation	IAMDGC
Formation	2010s
Type	Research consortium
Headquarters	International
Fields	Genomics, Ophthalmology

International AMD Genomics Consortium The International AMD Genomics Consortium is a global research collaboration focused on the genetic architecture of age-related macular degeneration. The consortium brings together investigators from institutions such as Massachusetts General Hospital, University of Cambridge, University of Michigan, Karolinska Institutet, and University of Oxford to integrate data from cohorts including the UK Biobank, Rotterdam Study, NHS, Framingham Heart Study and population biobanks across United States, Sweden, Netherlands and United Kingdom. Its work intersects with projects and organizations like the 1000 Genomes Project, Genome-wide association study, International HapMap Project, European Bioinformatics Institute and Wellcome Trust.

History

The consortium was formed in the 2010s through initiative among researchers at Harvard Medical School, Massachusetts Eye and Ear, Johns Hopkins University, Imperial College London, Uppsala University and the Broad Institute following seminal studies from groups at Age-Related Eye Disease Study (AREDS), Beaver Dam Eye Study and the Blue Mountains Eye Study. Early collaborations incorporated datasets from the Wellcome Trust Case Control Consortium, the International HapMap Project and the 1000 Genomes Project to perform multicenter genome-wide association study meta-analyses, leveraging methods developed at University of California, San Francisco, Stanford University, and King's College London.

Objectives and Scope

The consortium's objectives include identifying common and rare variants associated with age-related macular degeneration across diverse ancestries, mapping causal genes, and elucidating pathways for therapeutic targeting. It aims to harmonize genotype and phenotype data from clinical centers like Moorfields Eye Hospital and research hubs such as the National Eye Institute and European Molecular Biology Laboratory to inform translational research linked to drug development at pharmaceutical partners including Novartis, Genentech, Roche and Regeneron Pharmaceuticals.

Organizational Structure and Membership

Governance involves steering committees, analysis working groups, and phenotype subcommittees with representatives from academic centers including Yale University, Columbia University, University of Pennsylvania, McGill University and Monash University. Membership spans investigators affiliated with consortia and initiatives such as the International Human Genome Sequencing Consortium, Human Cell Atlas, All of Us Research Program and national funding bodies like the National Institutes of Health, European Research Council, Wellcome Trust and Medical Research Council.

Major Research Contributions

The consortium led landmark meta-analyses that expanded risk loci from early discoveries at CFH and ARMS2 to dozens of loci implicating complement, lipid, and extracellular matrix pathways. Major publications built on frameworks established at the Broad Institute, Harvard T.H. Chan School of Public Health, Yale School of Medicine and Monash Institute of Medical Research and influenced studies employing methods from PLINK developers and statistical genetics groups at University of Chicago and University of Oxford. Contributions include fine-mapping of loci using reference panels from the 1000 Genomes Project and functional annotation tied to datasets at the ENCODE Project and Roadmap Epigenomics Consortium.

Collaborations and Partnerships

Partnerships include data partnerships with the UK Biobank, collaborative networks with the European Eye Epidemiology Consortium, and translational alliances with industry groups such as Pfizer and academic consortia like the International Rare Diseases Research Consortium and the Global Alliance for Genomics and Health. The consortium coordinates with regulatory and clinical stakeholders including Food and Drug Administration, European Medicines Agency and specialty bodies like the American Academy of Ophthalmology and Royal College of Ophthalmologists.

Data Sharing and Resources

The consortium emphasizes open-science principles by contributing summary statistics to repositories modeled after the European Genome-phenome Archive and by adopting data standards promoted by the Global Alliance for Genomics and Health and the FAIR principles. It integrates genotype imputation resources from the Haplotype Reference Consortium and annotation tools developed at European Bioinformatics Institute, National Center for Biotechnology Information, and computational platforms at the Broad Institute and Lawrence Berkeley National Laboratory.

Impact on Clinical Practice and Policy

Findings have informed clinical risk prediction models used in practice at centers like Moorfields Eye Hospital and influenced guideline discussions at organizations such as the American Academy of Ophthalmology and Royal College of Ophthalmologists, shaping screening strategies and biomarker development. The consortium's genetic discoveries accelerated translational programs at biotech firms including Alcon and Regeneron Pharmaceuticals and contributed evidence cited in policy deliberations involving the National Institutes of Health and payers in United States and United Kingdom.

Category:Genomics research organizations